GlaxoSmithKline Pakistan Limited (PSX:GLAXO)

Market Cap	134.78B
Revenue (ttm)	61.15B
Net Income (ttm)	8.10B
Shares Out	318.47M
EPS (ttm)	25.43
PE Ratio	16.65
Forward PE	n/a
Dividend	10.00 (2.34%)
Ex-Dividend Date	Apr 18, 2025

Volume	848,325
Average Volume	543,013
Open	428.00
Previous Close	427.62
Day's Range	417.50 - 430.00
52-Week Range	125.60 - 481.00
Beta	0.36
RSI	58.72
Earnings Date	Aug 22, 2025

About GlaxoSmithKline Pakistan

GlaxoSmithKline Pakistan Limited operates as a biopharma company in Pakistan. It deals in anti-infective, dermatology, respiratory, immunology, oncology, infectious diseases, HIV, and vaccines therapy areas. The company sells its products under the Augmentin, Velosef, Amoxil, Dermovate, Clobevate, Betnovate, Calpol, and Cutivate brands. It also exports its products. The company was founded in 2001 and is headquartered in Karachi, Pakistan. GlaxoSmithKline Pakistan Limited is a subsidiary of GSK plc.

• Industry: Pharmaceuticals
• Sector: Healthcare
• Founded: 2001
• Employees: 1,700
• Stock Exchange: Pakistan Stock Exchange
• Ticker Symbol: GLAXO

Financial Performance

In 2024, GlaxoSmithKline Pakistan's revenue was 61.19 billion, an increase of 23.21% compared to the previous year's 49.66 billion. Earnings were 6.54 billion, an increase of 1124.09%.